You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

40 Results
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sep 2023
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sep 2023
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI), 
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2024
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
Feb 2023
Regimen
Cancer Type:
Genitourinary, 
Penile
Intent: Neoadjuvant, Palliative
Mar 2021
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2021
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Sep 2021
Regimen
Intent: Palliative
May 2019
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
May 2019
Regimen
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
  • triptorelin
May 2019
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced or Recurrent Endometrial Cancer
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of metastatic gastric cancer (mGC) or adenocarcinoma of the gastroesophageal junction (GEJ) in adult patients, according to clinical criteria
Nov 2022

Pages